Effects of mood stabilizers on marble-burying behavior in mice: Involvement of GABAergic system

Psychopharmacology

Volumn 226, Issue 2, 2013, Pages 295-305

  Egashira, Nobuaki ^a,b   Abe, Moe ^a   Shirakawa, Atsunori ^a   Niki, Tomiko ^a   Mishima, Kenichi ^a   Iwasaki, Katsunori ^a   Oishi, Ryozo ^b   Fujiwara, Michihiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Carbamazepine; GABAA receptor; Lamotrigine; Lithium; Marble burying behavior; Mood stabilizers; Obsessive compulsive disorder; Valproate

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BACLOFEN; BICUCULLINE; CARBAMAZEPINE; LAMOTRIGINE; LITHIUM CARBONATE; MOOD STABILIZER; MUSCIMOL; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DRUG EFFECT; GABAERGIC SYSTEM; LOCOMOTION; MALE; MARBLE BURYING BEHAVIOR; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANIMALS; ANTIPSYCHOTIC AGENTS; BACLOFEN; BEHAVIOR, ANIMAL; BICUCULLINE; CARBAMAZEPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA-AMINOBUTYRIC ACID; LITHIUM CARBONATE; MALE; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; MUSCIMOL; OBSESSIVE-COMPULSIVE DISORDER; RECEPTORS, GABA-A; TRIAZINES; VALPROIC ACID;

EID: 84877139652     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2904-9     Document Type: Article

References (71)

1. Albelda N, Joel D (2012) Animal models of obsessive-compulsive disorder: exploring pharmacology and neural substrates. Neurosci Biobehav Rev 36:47-63
2. 2+ channels in cultured rat hippocampal neurons stimulated with glutamate receptor agonists. Neuropharmacology 38:1349-1359
3. Arnold PD, Rosenberg DR, Mundo E, Tharmalingam S, Kennedy JL, Richter MA (2004) Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl) 174:530-538
4. Arnold PD, Sicard T, Burroughs E, Richter MA, Kennedy JL (2006) Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry 63:769-776
5. Biggs CS, Pearce BR, Fowler LJ, Whitton PS (1992) Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain: an in vivo microdialysis study. J Neurochem 59:1702-1708
6. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF (2006) A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatr 11:622-632
7. Braff DL, Geyer MA (1990) Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 47:181-188
8. Brody SA, Geyer MA, Large CH (2003) Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology (Berl) 169:240-246
9. Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S (2005) Glutamatergic dysfunction in OCD. Neuropsychopharmacology 30:1735-1740
10. Chiu CT, Chuang DM (2010) Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther 128:281-304
11. Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH (2005) Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 58:424-428
12. Cunningham MO, Jones RS (2000) The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology 39:2139-2146
13. Dalvi A, Rodgers RJ (1996) GABAergic influences on plus-maze behaviour in mice. Psychopharmacology (Berl) 128:380-397
14. A receptor in the molecular mechanisms of combined selective serotonin reuptake inhibitor-antipsychotic treatment. Int J Neuropsychopharmacol 14:143-155
15. 1 receptor in inhibiting activity of fluvoxamine on marble-burying behavior: comparison with paroxetine. Eur J Pharmacol 563:149-154
16. Egashira N, Okuno R, Abe M, Matsushita M, Mishima K, Iwasaki K, Oishi R, Nishimura R, Matsumoto Y, Fujiwara M (2008a) Calcium-channel antagonists inhibit marble-burying behavior in mice. J Pharmacol Sci 108:140-143
17. Egashira N, Okuno R, Harada S, Matsushita M, Mishima K, Iwasaki K, Nishimura R, Oishi R, Fujiwara M (2008b) Effects of glutamate-related drugs on marble-burying behavior in mice: implications for obsessive-compulsive disorder. Eur J Pharmacol 586:164-170
18. Flood DG, Choinski M, Marino MJ, Gasior M (2009) Mood stabilizers increase prepulse inhibition in DBA/2NCrl mice. Psychopharmacology (Berl) 205:369-377
19. Foreman MM, Hanania T, Eller M (2009) Anxiolytic effects of lamotrigine and JZP-4 in the elevated plus maze and in the four plate conflict test. Eur J Pharmacol 602:316-320
20. Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS (1989) Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry 46:36-44
21. Greist JH, Bandelow B, Hollander E, Marazziti D, Montgomery SA, Nutt DJ, Okasha A, Swinson RP, Zohar J, World Council of Anxiety (2003) WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectr 8:7-16
22. Hirano K, Kimura R, Sugimoto Y, Yamada J, Uchida S, Kato Y, Hashimoto H, Yamada S (2005) Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors. Brit J Pharmacol 144:695-702
23. Hoenig K, Hochrein A, Quednow BB, Maier W, Wagner M (2005) Impaired prepulse inhibition of acoustic startle in obsessive-compulsive disorder. Biol Psychiatry 57:1153-1158
24. Hollander E, Dell'Osso B (2006) Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder. Int Clin Psychopharmacol 21:189-191
25. 1A receptor activation. Eur J Pharmacol 380:R1-R3
26. 1A receptor agonism. Brain Res 1049:182-190
27. 1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice. Jpn J Pharmacol 68:65-70
28. B1 receptor isoforms in tests of unconditioned anxiety. Psychopharmacology (Berl) 190:541-553
29. Jenike MA, Baier L, Minichiello WE (1998) Obsessive-compulsive disorders: practical management. Mosby, St. Louis
30. Joel D, Doljansky J, Schiller D (2005) 'Compulsive' lever pressing in rats is enhanced following lesions to the orbital cortex, but not to the basolateral nucleus of the amygdala or to the dorsal medial prefrontal cortex. Eur J Neurosci 21:2252-2262
31. Johannessen CU (2000) Mechanisms of action of valproate: a commentatory. Neurochem Int 37:103-110
32. Kaster MP, Raupp I, Binfaré RW, Andreatini R, Rodrigues AL (2007) Antidepressant-like effect of lamotrigine in the mouse forced swimming test: evidence for the involvement of the noradrenergic system. Eur J Pharmacol 565:119-124
33. B receptor agonists, partial agonists, antagonists and modulators: design and therapeutic prospects. Eur J Pharm Sci 5:355-384
34. + channels. Mol Pharmacol 54:712-721
35. Londei T, Valentini AMV, Leone VG (1998) Investigative burying by laboratory mice may involve non-functional, compulsive, behaviour. Behav Brain Res 94:249-254
36. Löscher W (1999) Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 58:31-59
37. 1A receptor in mice: implications for obsessive-compulsive disorder. J Pharmacol Sci 99:154-159
38. Menzies L, Chamberlain SR, Laird AR, Thelen SM, Sahakian BJ, Bullmore ET (2008) Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofronto-striatal model revisited. Neurosci Biobehav Rev 32:525-549
39. Munro G, Erichsen HK, Mirza NR (2007) Pharmacological comparison of anticonvulsant drugs in animal models of persistent pain and anxiety. Neuropharmacology 53:609-618
40. Murakami T, Okada M, Kawata Y, Zhu G, Kamata A, Kaneko S (2001) Determination of effects of antiepileptic drugs on SNAREs-mediated hippocampal monoamine release using in vivo microdialysis. Br J Pharmacol 134:507-520
41. 2+ elevating to depressing. J Neurosci 15:5065-5077
42. B receptor-mediated regulation of glutamate-activated calcium transients in hypothalamic and cortical neuron development. J Neurophysiol 82:94-102
43. Okada M, Hirano T, Mizuno K, Chiba T, Kawata Y, Kiryu K, Wada K, Tasaki H, Kaneko S (1997) Biphasic effects of carbamazepine on the dopaminergic system in rat striatum and hippocampus. Epilepsy Res 28:143-153
44. Okada M, Hirano T, Mizuno K, Kawata Y, Wada K, Murakami T, Tasaki H, Kaneko S (1998) Effects of carbamazepine on hippocampal serotonergic system. Epilepsy Res 31:187-198
45. Ong JC, Brody SA, Large CH, Geyer MA (2005) An investigation of the efficacy of mood stabilizers in rodent models of prepulse inhibition. J Pharmacol Exp Ther 315:1163-1171
46. Owens DF, Boyce LH, Davis MB, Kriegstein AR (1996) Excitatory GABA responses in embryonic and neonatal cortical slices demonstrated by gramicidin perforated-patch recordings and calcium imaging. J Neurosci 16:6414-6423
47. Pasquini M, Biondi M (2006) Mematine augmentation for refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatr 30:1173-1175
48. Poyurovsky M, Weizman R, Weizman A, Koran L (2005) Memantine for treatment-resistant OCD. Am J Psychiatry 162:2191-2192
49. Rasmussen SA, Eisen JL (1992) The epidemiology and clinical features of obsessive-compulsive disorder. Psychiatr Clin North Am 15:743-758
50. Rogawski MA, Löscher W (2004) The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5:553-564
51. Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ (2000) Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatr 39:1096-1103
52. Rosenberg DR, MacMillan SN, Moore GJ (2001) Brain anatomy and chemistry may predict treatment response in paediatric obsessive-compulsive disorder. Int J Neuropsychopharmacol 4:179-190
53. Rotge JY, Langbour N, Guehl D, Bioulac B, Jaafari N, Allard M, Aouizerate B, Burbaud P (2010) Gray matter alterations in obsessive-compulsive disorder: an anatomic likelihood estimation meta-analysis. Neuropsychopharmacology 35:686-691
54. Santiago M, Westerink BHC (1992) The role of GABA receptors in the control of nigrostriatal dopaminergic neurons: dual-probe microdialysis study in awake rats. Eur J Pharmacol 219:175-181
55. Sasson Y, Zohar J, Chopra M, Lustig M, Iancu I, Hendler T (1997) Epidemiology of obsessive-compulsive disorder: a world view. J Clin Psychiatr 58:7-10
56. Schilman EA, Klavir O, Winter C, Sohr R, Joel D (2010) The role of the striatum in compulsive behavior in intact and orbitofrontal-cortex-lesioned rats: possible involvement of the serotonergic system. Neuropsychopharmacology 35:1026-1039
57. Stahl M (2000) Neuroscientific basis and practical application. In: Stahl M (ed) Essential psychopharmacology, 2nd edn. Cambridge University Press, New York, pp 316-317
58. 2+ currents in cortical neurons: functional implications. Eur J Pharmacol 307:113-116
59. Stein DJ (2000) Neurobiology of the obsessive-compulsive spectrum disorders. Biol Psychiatry 47:296-304
60. Sugimoto Y, Yamamoto M, Tagawa N, Kobayashi Y, Mitsui-Saitoh K, Hotta Y, Yamada J (2011) Differences between mice strains in response to paroxetine in the forced swimming test: involvement of serotonergic or noradrenergic systems. Eur J Pharmacol 672:121-125
61. Sugiyama A, Saitoh A, Iwai T, Takahashi K, Yamada M, Sasaki-Hamada S, Oka J, Inagaki M, Yamada M (2012) Riluzole produces distinct anxiolytic-like effects in rats without the adverse effects associated with benzodiazepines. Neuropharmacology 62:2489-2498
62. Swerdlow NR, Benbow CH, Zisook S, Geyer MA, Braff DL (1993) A preliminary assessment of sensorimotor gating in patients with obsessive compulsive disorder. Biol Psychiatry 33:298-301
63. Swerdlow NR, Paulsen J, Braff DL, Butters N, Geyer MA, Swenson MR (1995) Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. J Neurol Neurosurg Psychiatry 58:192-200
64. Tam WC, Sewell KW, Deng HC (1998) Information processing in schizophrenia and bipolar disorder: a discriminant analysis. J Nerv Ment Dis 186:597-603
65. Thomas A, Burant A, Bui N, Graham D, Yuva-Paylor LA, Paylor R (2009) Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety. Psychopharmacology (Berl) 204:361-373
66. Umeda K, Suemaru K, Todo N, Egashira N, Mishima K, Iwasaki K, Fujiwara M, Araki H (2006) Effects of mood stabilizers on the disruption of prepulse inhibition induced by apomorphine or dizocilpine in mice. Eur J Pharmacol 553:157-162
67. Van Ameringen M, Mancini C, Patterson B, Bennett M (2006) Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress Anxiety 23:1-5
68. Wang SJ, Huang CC, Hsu KS, Tsai JJ, Gean PW (1996) Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones. Neuroreport 7:3037-3040
69. Winter C, Flash S, Klavir O, Klein J, Sohr R, Joel D (2008) The role of the subthalamic nucleus in 'compulsive' behavior in rats. Eur J Neurosci 27:1902-1911
70. Zangrossi H Jr, Leite JR, Graeff FG (1992) Anxiolytic effect of carbamazepine in the elevated plus-maze: possible role of adenosine. Psychopharmacology (Berl) 106:85-89
71. Zarrindast MR, Ghadimi M, Ramezani-Tehrani B, Sahebgharani M (2006) Effect of GABA receptor agonists or antagonists on morphine-induced Straub tail in mice. Int J Neurosci 116:963-973